JP2025502208A - トリプタミン組成物および方法 - Google Patents
トリプタミン組成物および方法 Download PDFInfo
- Publication number
- JP2025502208A JP2025502208A JP2024541809A JP2024541809A JP2025502208A JP 2025502208 A JP2025502208 A JP 2025502208A JP 2024541809 A JP2024541809 A JP 2024541809A JP 2024541809 A JP2024541809 A JP 2024541809A JP 2025502208 A JP2025502208 A JP 2025502208A
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharma
- ceutically acceptable
- acceptable salt
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263299599P | 2022-01-14 | 2022-01-14 | |
| US63/299,599 | 2022-01-14 | ||
| US202263384704P | 2022-11-22 | 2022-11-22 | |
| US63/384,704 | 2022-11-22 | ||
| PCT/EP2023/050702 WO2023135237A1 (en) | 2022-01-14 | 2023-01-13 | Tryptamine compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025502208A true JP2025502208A (ja) | 2025-01-24 |
| JPWO2023135237A5 JPWO2023135237A5 (https=) | 2026-01-20 |
| JP2025502208A5 JP2025502208A5 (https=) | 2026-01-20 |
Family
ID=85018123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541809A Pending JP2025502208A (ja) | 2022-01-14 | 2023-01-13 | トリプタミン組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250051279A1 (https=) |
| EP (1) | EP4463440A1 (https=) |
| JP (1) | JP2025502208A (https=) |
| KR (1) | KR20240134951A (https=) |
| AU (1) | AU2023207801B2 (https=) |
| CA (1) | CA3259235A1 (https=) |
| IL (1) | IL313889A (https=) |
| MX (1) | MX2024008691A (https=) |
| WO (1) | WO2023135237A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| ID28302A (id) | 1999-01-14 | 2001-05-10 | Teijin Ltd | Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu |
| GB0114272D0 (en) | 2001-06-12 | 2001-08-01 | Optinose As | Nasal delivery device |
| NZ514442A (en) | 1999-03-03 | 2003-08-29 | Optinose As | Nasal delivery device |
| GB0121568D0 (en) | 2001-09-06 | 2001-10-24 | Optinose As | Nasal delivery device |
| GB0019715D0 (en) | 2000-08-10 | 2000-09-27 | Pa Consulting Services | Device for delivering physiologically active agent in powdered form |
| ZA200306564B (en) | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
| JP4795637B2 (ja) | 2001-09-28 | 2011-10-19 | カーブ テクノロジー,インコーポレイティド | 鼻ネブライザー |
| GB0207422D0 (en) | 2002-03-28 | 2002-05-08 | Optinose As | Nasal devices |
| GB0207817D0 (en) | 2002-04-04 | 2002-05-15 | Optinose As | Nasal devices |
| GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20240096817A (ko) * | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12042564B2 (en) * | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
| JP2023544724A (ja) * | 2020-10-02 | 2023-10-25 | サイビン アイアールエル リミテッド | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
-
2023
- 2023-01-13 US US18/720,922 patent/US20250051279A1/en active Pending
- 2023-01-13 WO PCT/EP2023/050702 patent/WO2023135237A1/en not_active Ceased
- 2023-01-13 AU AU2023207801A patent/AU2023207801B2/en active Active
- 2023-01-13 CA CA3259235A patent/CA3259235A1/en active Pending
- 2023-01-13 JP JP2024541809A patent/JP2025502208A/ja active Pending
- 2023-01-13 MX MX2024008691A patent/MX2024008691A/es unknown
- 2023-01-13 IL IL313889A patent/IL313889A/en unknown
- 2023-01-13 EP EP23700949.3A patent/EP4463440A1/en active Pending
- 2023-01-13 KR KR1020247026687A patent/KR20240134951A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3259235A1 (en) | 2023-07-20 |
| AU2023207801B2 (en) | 2026-01-22 |
| WO2023135237A1 (en) | 2023-07-20 |
| KR20240134951A (ko) | 2024-09-10 |
| EP4463440A1 (en) | 2024-11-20 |
| MX2024008691A (es) | 2024-07-19 |
| IL313889A (en) | 2024-08-01 |
| US20250051279A1 (en) | 2025-02-13 |
| AU2023207801A1 (en) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250213527A1 (en) | Formulations of psilocybin analogs and methods of use | |
| AU2022342266B2 (en) | Combination drug therapies | |
| JP2025510942A (ja) | 亜酸化窒素及び5-ht2a受容体作動薬の組み合わせ | |
| JP2025505745A (ja) | フェネチルアミン誘導体、組成物、及び使用方法 | |
| US20250236589A1 (en) | Therapeutic phenethylamine compositions and methods of use | |
| AU2023207801B2 (en) | Tryptamine compositions and methods | |
| KR20250097837A (ko) | 펜에틸아민 화합물, 조성물, 및 사용 방법 | |
| US20250205198A1 (en) | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods | |
| JP2025531630A (ja) | トリプタミン化合物、組成物、及び使用方法 | |
| CN118632835A (zh) | 色胺组合物和方法 | |
| JP2026513655A (ja) | フェネチルアミン化合物、組成物、及び使用方法 | |
| CN118234708A (zh) | 裸头草碱类似物的调配物和使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260109 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260109 |